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Adherence to treatment — a pivotal issue 
in long-term treatment of patients with 
cardiovascular diseases. An expert 
standpoint
ABSTRACT
The adherence to treatment is defined as the extent to which a person’s behaviour, including taking medication, 
following a diet, and/or executing lifestyle changes, corresponds with agreed recommendations from a health-
care provider. Non-adherence to medication may lead to increased morbidity, mortality, and costs to the 
healthcare system. Therefore, it is pivotal to know the patient’s true adherence to medication, understand 
the causes of low adherence, and take actions to improve adherence.
The authors assumed that individual, complex health education started during hospitalisation and continued 
after discharge, explaining the pathophysiology and symptoms of the disease, elucidating goals and potential 
benefits of treatment, and highlighting the risk of premature termination of therapy, with use of additional methods 
helping patients to remember treatment schedule will enhance adherence to treatment. There is an urgent need 
to develop and test a dedicated procedure covering all these activities.
Introduction. A substantial proportion of patients with cardiovascular diseases do not respond to the 
treatment sufficiently [1–3]. Several factors of poor response to medication should be taken into ac-
count, including inadequate drug intake [4–6]. To systematise the phenomenon of following medical 
recommendations, the term “adherence” was proposed. The World Health Organisation (WHO) defines 
“adherence” as “the extent to which a person’s behaviour, including taking medication, following a diet, 
and/or executing lifestyle changes, corresponds with agreed recommendations from a healthcare pro-
vider” [7]. Adherence has been also defined as the “active, voluntary, and collaborative involvement of 
the patient in a mutually acceptable course of behaviour to produce a therapeutic result” [8]. Previously 
the term ‘compliance’ was widely used, particularly in negative concord as ‘non-compliance’. Nowadays 
‘compliance’ is associated with a more pejorative connotation than ‘adherence’ because ‘non-compliance 
issues’ are mostly patient-oriented without a deeper view into the different set of factors, e.g. obstacles 
identified in the healthcare system. Thus, currently in scientific deliberations we usually prefer usage of 
the term ‘adherence’ [9]. 
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The prevalence and consequences of 
non-adherence 
According to the Food and Drug Administration 
data, from 30 to 50% of patients do not exactly adhere 
to recommendations received from their healthcare 
providers, which significantly increases the risk of death. 
These data were confirmed in several studies [6,10–16]. 
Non-adherence to medication may lead to increased 
morbidity, mortality, and costs to the healthcare sys-
tem [8,16–19]. Therefore, it is pivotal to know the true 
patient’s adherence to medication, understand the 
causes of low adherence, and take actions to improve 
adherence [20]. 
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Results of the Prospective Registry Evaluating 
Myocardial Infarction: Event and Recovery (PREMIER) 
trial showed that failure of treatment plan implementa-
tion is associated with poor clinical outcome [21]. In 
1521 myocardial infarction survivors at one month after 
discharge from the hospital with the recommendation 
of combination therapy with three drugs (aspirin, a be-
ta-blocker, and a statin), 12% of patients discontinued 
treatment with all three drugs, 4% — with two drugs, 
and 18% — with one drug. One-year survival rate of 
patients who completely stopped their medication was 
significantly lower compared with those who contin-
ued their therapy (88.5% vs. 97.7%). Discontinuation 
of treatment was an independent risk factor for death 
(hazard ratio 3.81). Multivariate analysis showed that 
the probability of discontinuation of all three drugs 
was higher among those with higher education (haz-
ard ratio 1.76). The impact of older age on treatment 
discontinuation was higher among women (hazard 
ratio 1.77) than among men (hazard ratio 1.23) [21]. 
The Prospective Urban Rural Epidemiology  (PURE) 
study showed that adherence to secondary prevention 
therapy was more influenced by general socioeconomic 
factors at the national level than to individual factors, 
such as age, gender, education level, smoking, body 
mass index (BMI), hypertension, and diabetes [22]. It 
is worth mentioning, however, that studies based solely 
on a quantitative approach may underestimate the true 
nature of the non-adherence phenomenon, and quali-
tative studies are highly anticipated to detect nuances 
that can deteriorate adherence [9]. 
Determinants of non-adherence
In several studies the age of patients was indi-
cated as one of the factors affecting adherence to 
medication [8,14,18–19,23–24]. Comorbidity burden 
increasing with age is associated with the necessity of 
polypharmacy. Elderly patients often do not understand 
the reasons for the complexity of the treatment, and 
have problems with remembering and adapting to the 
treatment schedule [25]. Holt et al. conducted a qual-
itative study based on a focus group, which revealed 
that memory-related problems and forgetfulness were 
factors mostly reported by the elderly in the context of 
the non-adherence phenomenon. Patients emphasised 
that knowledge about the nature and seriousness of 
the primary disease, i.e. hypertension, can improve 
adherence to recommended therapy. These findings 
may suggest the potential target of new interventions 
[26]. The Pennsylvania Pharmaceutical Assistance 
Contract for the Elderly (PACE) study showed that in 
elderly patients with hypertension, adherence to the 
treatment plan was worse in the coexistence of asthma 
or chronic obstructive pulmonary disease (odds ratio 
[OR] = 0.43), depression (OR = 0.5), gastrointestinal 
disorders (OR = 0.59), or musculoskeletal diseases 
(OR = 0.63) compared with hypertensive patients with-
out concomitant diseases (OR = 1.0) [27]. Moreover, it 
was revealed that polypharmacy has a negative impact 
on the implementation of the treatment plan [18]. In 
another study, the co-existence of diabetes was found 
to be an independent factor reducing adherence to 
treatment [14]. Low adherence occurs in all age groups; 
however, older patients are particularly exposed to 
multiple challenges regarding this issue, including 
difficulty hearing, comprehending, and remembering 
instructions, managing multiple medications, and 
tolerating side effects of medication and drug-drug 
interactions [28]. Due to differences of cultural, social, 
and medical nature, the adherence determinants for 
distinct patient populations differ [24]. Many studies 
have tried to identify patients jeopardised with future 
failure to follow the doctor’s recommendations after 
hospital discharge [28–29]. Several different factors 
associated with low adherence to medication were 
identified, including female gender [8,18,25,27,30], 
low level of education [8,17], adverse effects of therapy 
[31], insufficient instructions given to patients [31], poor 
financial status preventing purchasing of medicines 
[31–33], lack of acceptance of the need for treatment 
by the patient [31], and poor relationship between the 
patient and medical staff [31–34]. 
Failure to follow the treatment plan is a relative-
ly common problem, which is a serious and often 
underestimated factor limiting the effectiveness of 
treatment. Unfortunately, non-adherence to treatment 
often remains both common and difficult to detect [34]. 
Identifying the key determinants of low adherence and 
early discontinuation of treatment may aid in the devel-
opment of interventions aimed at increasing adherence 
and addressing this high-risk population, in order to 
improve health outcomes [34–35].
The adherence assessment 
There are some direct and indirect methods of 
assessing adherence to treatment; however, there is 
no single “gold standard” or a universal tool for deter-
mining the level of adherence [36–39]. Asking patients 
is the simplest and most frequently used method of 
adherence assessment. However, it has been shown 
that the data obtained in this way have limited credibility 
[14,20]. Objectification of patient-reported information 
is usually difficult and costly. On the other hand, some 
experts argue that the positive relationship between 
subjective data (e.g. questionnaires) and objective 
data (e.g. obtained from the medical reports) is high, 
so validated tools should be considered as a reliable 
instrument aimed at detecting non-adherence problems 
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[40]. The application of specially developed question-
naires or scales to assess the risk of low adherence 
may be helpful in allowing extensive screening of pa-
tients. Moreover, well-designed questionnaires may also 
identify obstacles, gaps in patients’ knowledge, and the 
problems in cooperation with patients. Nevertheless, 
even access to validated questionnaires does not di-
minish all potential obstacles associated with this social 
technique. For instance, due to memory-related issues, 
questionnaires can only measure non-adherence within 
a period of several weeks, which is not satisfactory from 
the scientific point of view and provides a limited scope 
of information for healthcare providers [40].
Recently, Buszko et al. [41] published an article 
validating the Adherence in Chronic Diseases Scale 
(ACDS). The ACDS allows assessment of adherence 
itself, as well as identification of the most important 
factors influencing adherence, such as: acceptance 
of a therapy plan, cooperation between a patient and 
health care professionals, and the economic status 
of a patient [42–44]. The ACDS scores range from 
0 to 28 points. Results below 21 points, between 
21–26 points, and above 26 points correspond respec-
tively to low, medium, and high adherence, respectively. 
The internal consistency of the ACDS final version 
was assessed using Cronbach’s alpha coefficient, 
and the value of 0.752 confirmed high reliability and 
homogeneity of the questionnaire [41]. The ACDS was 
subsequently applied in a single-centre, prospective, 
observational cohort clinical study with a six-month 
follow-up [45]. In a population of 221 patients with 
myocardial infarction treated with PCI, lower scores for 
ACDS items 2 and 3 were associated with increased 
risk of acute coronary syndrome during follow-up (for 
item 2: 3.11±0.68 vs. 3.45±0.73; p=0.02, and for 
item 3: 3.28±0.89 vs. 3.64±0.64; p=0.04), indicating 
the predictive value of these items [45]. The scale is 
simple to use and may be applied in everyday medical 
practice and for research purposes [44–45]. It can be 
successfully used as a tool to support medical staff in 
identifying patients requiring personalised educational 
activities [41]. 
Summary 
Medication adherence is an issue of growing 
concern for those working to improve health system 
performance, and promoting adherence to medications 
offers a rare opportunity to simultaneously improve 
health outcomes while reducing costs. Jankowski at 
al. [46] pointed out different healthcare-related factors 
and patient-related factors affecting proper treatment 
of patients with cardiovascular diseases. According to 
Jankowska-Polanska at al. [47], the knowledge deficits 
contribute to a lack of adherence and worse clinical 
outcome. Therefore, education of patients regarding 
the risks and benefits of treatment is pivotal to avoid 
premature discontinuation of medication [48]. Never-
theless, no standard approach has been developed. 
Pharmaceutical care including educational interven-
tions and reminding methods in patients with chronic 
diseases is also beneficial, both to the patients and 
to the entire healthcare system [49]. To sum up, we 
should admit that inter-professional collaboration is 
needed to improve adherence and outcomes. Thus, we 
should reveal the concept of ‘concordance’ as the deep 
agreement between patients and health-care providers, 
where the patients’ needs are the matter of paramount 
importance [50].
Conclusions 
The authors assumed that individual, complex health 
education started during hospitalisation and continued 
after discharge, explaining the pathophysiology and 
symptoms of the disease, elucidating goals and po-
tential benefits of treatment, and highlighting the risk of 
premature termination of therapy, with use of additional 
methods helping patients to remember the treatment 
schedule will enhance adherence to treatment. There 
is an urgent need to develop and test a dedicated pro-
cedure covering all these activities.
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